Cancer Drug Price Cap 2026: NPPA’s 30% Trade Margin Rule Explained

Last updated: 19 October 2026 (IST) | Author: Deepak Sethia, JamaDhan Stock Market Institute

NPPA has capped trade margins on 137 non-scheduled anti-cancer drugs at 30% of MRP, effective 9 November 2026. Prices of some brands could fall by up to 70%, depending on each product’s current mark-up.

Cancer treatment is expensive for families, not just emotionally but financially. On 17 October 2026, the drug price regulator NPPA issued a notification capping the trade margin on these medicines, and the government said prices could fall by up to 70% depending on the brand (PIB release on cancer drug trade margin cap). Hospital and pharma stocks with cancer-drug exposure traded lower on 19 October (Upstox market report).

This article explains, in simple terms, what a trade margin is, how the new rule works, and which sectors are affected. It is for education only and contains no stock recommendations. New to markets? Start with our stock market basics guide.

What is a trade margin?

A medicine passes through several hands: manufacturer, stockist or distributor, chemist or hospital pharmacy, and finally the patient. The trade margin is what these middle players earn between the manufacturer’s selling price and the MRP (BusinessLine analysis).

These 137 drugs were “non-scheduled,” which means they sat outside regular price control, giving companies and traders more freedom to set prices (BusinessLine analysis). Government data cited in media reports put the average trade mark-up on these cancer drugs at about 170%, and in some cases as high as 700% (CNBC-TV18).

How does the 30% trade margin rule work?

The new MRP equals the manufacturer’s price to the stockist (PTS), plus a trade margin of at most 30% of MRP, plus GST. In other words, traders can add at most 42.86% on top of the stockist price (BusinessLine analysis).

Worked example: Suppose the stockist price is ₹1,000 and GST is 5%. The maximum new MRP comes to ₹1,500.

Some points to note:

• The list includes widely used medicines such as pembrolizumab, osimertinib, bevacizumab and denosumab (PIB release).
• Patented drugs are covered as well (NPPA Gazette).
• When a manufacturer supplies a hospital directly, the hospital is treated as the stockist (BusinessLine analysis).
• Manufacturers must report revised prices within 7 days of the notification, and the new prices apply from 9 November 2026 (PIB release).
• Manufacturers must maintain current production and supply levels (PIB release).

Has this happened before?

Yes. In 2019, NPPA ran a similar exercise on 42 cancer drugs, and the MRPs of 526 brands fell by up to 90% (PIB release).

Why now? The Supreme Court angle

The rule follows a series of court developments:

• 29 September 2026: The Supreme Court called a ten-times mark-up on cancer drugs “carnage” and argued for a uniform 16% margin (India Today).
• 12 October 2026: The Centre told the court that a 30% cap would save patients about ₹2,500 crore a year. The bench asked why all medicines could not be covered and gave the government until 27 October to present a plan (BusinessLine).
• 17 October 2026: NPPA’s Gazette notification and PIB release were published (PIB release).

Sector impact: who feels what?

Hospitals. Many hospitals sell cancer drugs through their own pharmacies, so brokerages expect hospitals to absorb part of the squeeze (Tradebrains). Nuvama estimates the impact at roughly 1% to 4% for large chains, with some recovery possible through pricing changes on other services. These are brokerage estimates, not confirmed figures (CNBC-TV18). Hospitals focused only on cancer care are more exposed (CNBC-TV18).

Hospital stocks had already fallen 11% to 20% in the previous month, and the market had feared a stricter 16% cap (CNBC-TV18, Tradebrains). Markets often react to the surprise in a policy as much as to the headline.

Pharma companies. The cap applies to trade margins, not directly to what manufacturers earn. NPPA says the aim is to protect “legitimate manufacturer revenues” (PIB release). The actual impact depends on which products each company has on the list (Upstox market report). The pharma industry body IPA welcomed the move (Business Standard).

Chemists and distributors. The chemists’ association AIOCD welcomed the cap and said high MRPs are printed by manufacturers, so genuine chemists should not be blamed (NewsMill).

Patients. Patients are the clearest beneficiaries. Lower MRPs should reduce out-of-pocket costs, and cheaper drugs may bring more patients into treatment over time (Upstox market report).

Second-order effects to watch

• Could caps spread? The Supreme Court has questioned steep mark-ups on saline drips and cardiac stents (New Indian Express). One analyst estimates pharmacy is 20% to 25% of hospital revenue, so wider caps would matter far more than this one (CNBC-TV18).
• Other charges may rise. Hospitals could raise admission or chemotherapy charges (Business Standard). This is easier with cash-paying patients than with insured ones (CNBC-TV18).
• Availability and launches. Experts warn that very tight price control could make some drugs or new launches less attractive to companies (CNBC-TV18).

Policy decisions rarely affect just one sector. The same pattern has played out with recent fuel export taxes and the IDBI Bank privatisation, which we have also covered on this site (fuel export windfall tax explainer, IDBI Bank privatisation explainer).

Key dates to track

• Within 7 days of 17 October: Manufacturers file revised prices (PIB release)
• 27 October: Supreme Court hearing (Tradebrains)
• 9 November: New MRPs take effect (PIB release)

Event days like these often bring extra volatility. To understand how markets price that uncertainty, read our guide to implied volatility and India VIX.

Learn to read policy news

Understanding how government policy affects a sector is a skill built through practice, not tips. JamaDhan’s free 7-day workshop, Trading Ki Pathsala, covers market basics, chart reading and how to read news calmly. Call +91-9257059361 or book a seat through JamaDhan’s Trading Ki Pathshala.

Disclaimer: This article is for educational purposes only and is not investment advice or a recommendation to buy or sell any security. Company names are mentioned only as factual context. JamaDhan’s SEBI Research Analyst registration is pending. Please consult a SEBI-registered advisor before investing.

Frequently asked questions